Scienture Shares Surge After FDA Clears Arbli and L1 Capital Snags 9.99% Stake

Introduction

Scienture Holdings, Inc. (NASDAQ: SCNX) is a Cayman Islands–based holding company focused on developing, commercializing, and distributing specialty pharmaceutical products. As of October 16, 2025, shares closed at $0.90, reflecting a 25.66% increase on a trading volume of 38,930,854 shares. The company trades under the ticker SCNX on the NASDAQ exchange and is known in Korea as “사이엔처 홀딩스.”

Corporate structure

Scienture Holdings’ principal operating subsidiary, Scienture LLC, is headquartered in Hauppauge, New York. Founded in 2019, Scienture LLC employs between 2 and 10 professionals specializing in pharmaceutical research and development. The parent company’s governance framework includes an independent-majority board, audit and compensation committees, and formal guidelines for executive remuneration, succession planning, and compliance oversight.

Pharmaceuticals by freestocks

Recent developments

In October 2025, the U.S. Food and Drug Administration approved the New Drug Application for SCN-102, to be marketed as Arbli™ (losartan potassium oral suspension, 10 mg/mL). That same month, Scienture announced the shipment of launch quantities of Arbli to its third-party logistics center and confirmed receipt of its first wholesaler order, initiating commercial distribution.

On October 7, 2025, L1 Capital Global Opportunities Master Fund, Ltd. filed a Schedule 13G disclosing a beneficial ownership stake of 9.99% in Scienture Holdings, with sole voting and dispositive power over its shares.

Financial and strategic aspects

The increase in Scienture’s share price on October 16 followed the FDA approval and related commercial milestones for Arbli, which contributes to a segment of the $1.5 billion global losartan potassium market projected for 2024. The company’s product pipeline includes:

• SCN-104 (CNS/Pain): drug-device combination for self-injection, in early development phases
• SCN-106 (CVS): biosimilar product for hospital use, progressing through human clinical trials
• SCN-107 (CNS/Pain): long-acting injection for post-operative care, with human studies underway

Corporate filings highlight a focus on strategic value creation, as seen in the Schedule 13G filing, and emphasize the importance of partnerships for licensing, co-marketing, and asset acquisitions to facilitate commercialization and expand market presence.

Market position and industry context

Operating within the pharmaceutical manufacturing sector, Scienture Holdings competes in specialty product segments targeting unmet medical needs. Its strategy merges in-house product development with third-party distribution, utilizing a lean organizational structure. The launch of Arbli allows the company to enter the antihypertensive market, where it will compete alongside established formulary players. The diversified pipeline and governance structures are designed to support potential revenue growth and maintain shareholder interests.

tl;dr

– October 2025: FDA approves SCN-102 (Arbli), and initial commercial shipments are commenced.
– October 7, 2025: L1 Capital reports a 9.99% passive stake via Schedule 13G.
– October 16, 2025: SCNX shares close at $0.90, up 25.66% on a high trading volume.
– Pipeline assets SCN-104, SCN-106, and SCN-107 advance through clinical stages, supporting the near-term commercialization outlook.